New trends in thromboxane and prostacyclin modulators

J M Dogné, X de Leval, J Delarge, J L David, B Masereel

Research output: Contribution to journalArticle

Abstract

Thromboxane A2 (TXA2) and prostacyclin (PGI2) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA2 / prostaglandin endoperoxide H2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A2. Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA2, several PGI2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A2 modulators mainly those which are under clinical evaluation or marketed.
Original languageEnglish
Pages (from-to)609-28
Number of pages20
JournalCurrent Medicinal Chemistry
Volume7
Issue number6
Publication statusPublished - Jun 2000

Fingerprint

Thromboxane A2
Thromboxanes
Epoprostenol
Muscle Contraction
Smooth Muscle
Prostaglandin H2 Receptors Thromboxane A2
Platelet Aggregation Inhibitors
Prostaglandin-Endoperoxide Synthases
Platelet Aggregation
Prostaglandins
Pharmaceutical Preparations

Keywords

  • Enzyme Inhibitors
  • Epoprostenol
  • Fibrinolytic Agents
  • Humans
  • Imidazoles
  • Receptors, Thromboxane
  • Sulfonamides
  • Thromboxane A2
  • Thromboxane-A Synthase

Cite this

Dogné, J M ; de Leval, X ; Delarge, J ; David, J L ; Masereel, B. / New trends in thromboxane and prostacyclin modulators. In: Current Medicinal Chemistry. 2000 ; Vol. 7, No. 6. pp. 609-28.
@article{ea9d3d28a0514da88606b1c0105f4842,
title = "New trends in thromboxane and prostacyclin modulators",
abstract = "Thromboxane A2 (TXA2) and prostacyclin (PGI2) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA2 / prostaglandin endoperoxide H2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A2. Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA2, several PGI2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A2 modulators mainly those which are under clinical evaluation or marketed.",
keywords = "Enzyme Inhibitors, Epoprostenol, Fibrinolytic Agents, Humans, Imidazoles, Receptors, Thromboxane, Sulfonamides, Thromboxane A2, Thromboxane-A Synthase",
author = "Dogn{\'e}, {J M} and {de Leval}, X and J Delarge and David, {J L} and B Masereel",
year = "2000",
month = "6",
language = "English",
volume = "7",
pages = "609--28",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

Dogné, JM, de Leval, X, Delarge, J, David, JL & Masereel, B 2000, 'New trends in thromboxane and prostacyclin modulators', Current Medicinal Chemistry, vol. 7, no. 6, pp. 609-28.

New trends in thromboxane and prostacyclin modulators. / Dogné, J M; de Leval, X; Delarge, J; David, J L; Masereel, B.

In: Current Medicinal Chemistry, Vol. 7, No. 6, 06.2000, p. 609-28.

Research output: Contribution to journalArticle

TY - JOUR

T1 - New trends in thromboxane and prostacyclin modulators

AU - Dogné, J M

AU - de Leval, X

AU - Delarge, J

AU - David, J L

AU - Masereel, B

PY - 2000/6

Y1 - 2000/6

N2 - Thromboxane A2 (TXA2) and prostacyclin (PGI2) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA2 / prostaglandin endoperoxide H2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A2. Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA2, several PGI2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A2 modulators mainly those which are under clinical evaluation or marketed.

AB - Thromboxane A2 (TXA2) and prostacyclin (PGI2) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA2 / prostaglandin endoperoxide H2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A2. Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA2, several PGI2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A2 modulators mainly those which are under clinical evaluation or marketed.

KW - Enzyme Inhibitors

KW - Epoprostenol

KW - Fibrinolytic Agents

KW - Humans

KW - Imidazoles

KW - Receptors, Thromboxane

KW - Sulfonamides

KW - Thromboxane A2

KW - Thromboxane-A Synthase

M3 - Article

C2 - 10702629

VL - 7

SP - 609

EP - 628

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 6

ER -